Implementation and Impact of Intimate Partner Violence Screening Expansion in the Veterans Health Administration: Protocol for a Mixed Methods Evaluation
Portnoy G, Relyea M, Dichter M, Iverson K, Presseau C, Brandt C, Skanderson M, Bruce L, Martino S. Implementation and Impact of Intimate Partner Violence Screening Expansion in the Veterans Health Administration: Protocol for a Mixed Methods Evaluation. JMIR Research Protocols 2024, 13: e59918. PMID: 39194059, PMCID: PMC11391160, DOI: 10.2196/59918.Peer-Reviewed Original ResearchConceptsVeterans Health AdministrationImpact of screeningINTERNATIONAL REGISTERED REPORT IDENTIFIERHealth care systemIntimate partner violenceIPV screeningQualitative interviewsCare systemHealth AdministrationConsolidated Framework for Implementation ResearchVeterans Health Administration facilitiesElectronic health record dataIntimate partner violence screeningMixed methods evaluationHealth record dataNational health care systemLongitudinal observational designPotential implementation barriersSignificant public health problemMen's health careClinical practice implicationsPatient populationMethod evaluationRE-AIMPublic health problemContribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study
Guillot J, Justice A, Gordon K, Skanderson M, Pariente A, Bezin J, Rentsch C. Contribution of Potentially Inappropriate Medications to Polypharmacy-Associated Risk of Mortality in Middle-Aged Patients: A National Cohort Study. Journal Of General Internal Medicine 2024, 1-10. PMID: 38831248, DOI: 10.1007/s11606-024-08817-4.Peer-Reviewed Original ResearchMiddle-aged patientsRisk of mortalityVeterans AffairsChronic medicationsVA patient populationIntegrated healthcare systemNational cohort studyAssociated with increased mortalityMiddle-aged individualsMechanism of injuryMiddle-aged peopleAssociated with mortalityInappropriate medicationsBeers criteriaHealthcare systemAttenuate riskCohort studyClinical characteristicsGeneral populationHyperpolypharmacyFollow-upPolypharmacyPatient populationBackgroundThe roleCox model